Dyne Therapeutics Management
Management criteria checks 2/4
Dyne Therapeutics' CEO is John Cox, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.036% of the company’s shares, worth $1.09M. The average tenure of the management team and the board of directors is 3.4 years and 5 years respectively.
Key information
John Cox
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 3.4yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Nov 12
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Nov 11Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
Sep 04Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 12Dyne Therapeutics EPS beats by $0.10
May 06CEO
John Cox (61 yo)
less than a year
Tenure
Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | 0.036% $ 1.1m | |
| Co-Founder & Advisor | no data | US$4.37m | no data | |
| Senior VP and Head of Finance & Administration | 4.3yrs | no data | 0.0058% $ 172.6k | |
| Chief Technical Officer | 1.6yrs | no data | no data | |
| Chief Scientific Officer | 3.4yrs | US$1.49m | 0.033% $ 981.2k | |
| Senior VP and Head of Corporate Communications & Investor Relations | 4.3yrs | no data | no data | |
| Senior VP & Head of Legal | 4.4yrs | no data | no data | |
| Chief Human Resource Officer | less than a year | no data | no data | |
| Chief Regulatory Affairs Officer | 4.5yrs | no data | no data | |
| Chief Medical Affairs Officer | 3.8yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
3.4yrs
Average Tenure
56.5yo
Average Age
Experienced Management: DYN's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | 0.036% $ 1.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6yrs | US$250.17k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$264.17k | 0.053% $ 1.6m | |
| Independent Chairman | 6.9yrs | US$283.17k | 0% $ 0 | |
| Independent Director | 6yrs | US$262.67k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$253.92k | 0.088% $ 2.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data |
5.0yrs
Average Tenure
61yo
Average Age
Experienced Board: DYN's board of directors are considered experienced (5 years average tenure).